Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

In the largest congregation of religious saints and sadhus, many images and stories of different ... Mahant Rajgiri Naga Baba lives in a retro 1972 Ambassador fitted with all the essentials.

Sanofi and Regeneron’s checkpoint inhibitor ... respectively, with Libtayo. The trial enrolled patients with advanced cervical cancer regardless of PD-L1 status. If approved, Libtayo will ...

"My duty as a citizen is to give any help and insight I can. Any chance the position comes with an Ambassador's residence?" (Gibson's concluding quip would seem to be a reference to him recently ...

Because public health agencies have learned that these patients had bird flu days or weeks after the person became ill, it has hampered efforts to find out how they were exposed and make sure they ...

If all goes as planned, Myerson says, the Truveta Genome Project will unlock insights into patient care and propel ... senior vice president of Regeneron and head of its Genetics Center.